How to Sequence Therapies in Diffuse Large B‑Cell Lymphoma Post‑CAR‑T Cell Failure. Curr. Treat. Options in Oncol. 2021 Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell maligna...
Besides the endeavors to enhance the functionality of CAR-T cell per se, optimization of the infusion and delivery strategies facilitates the breakthrough of the hurdles that limited the efficacy of this cancer immunotherapy. Here, we summarized the infusion and delivery strategies of CAR-T cell ...
as the complete response (1/17) and partial response (2/17) patients received both cell infusion and chemo/hormone ther- apy.115 However, the patient cohorts in these studies were small and highly diverse, in terms of cancer type, additional therapy and composition of the T cell infusion....
especially gastrointestinal cancers, and is emerging as a new target for cancer treatment. Satricabtagene autoleucel (satri-cel)/CT041 is an autologous chimeric antigen receptor (CAR) T cell targeting CLDN18.2, and the interim results of the CT041-CG4006 trial were reported in June...
1.αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib | Journal for ImmunoTherapy of Cancer (bmj.com) 2.CAR T-Cell Therapy Shows Early Potenti...
and infusion back to the patients. CAR-T cell immunotherapy has led to a significant improvement in the remission rates of hematological cancers. CAR-T cell therapy presently limited to hematological cancers, there are ongoing efforts to develop additional CAR constructs such as bispecific CAR, tand...
4. Donor-derived stem cell infusion for sustained pancytopenia after CD19 CAR-T therapy for relapsed patients post allogeneic stem cell transplantation.（CAR-T细胞治疗异基因造血干细胞移植（allo-HSCT）后复发病例的有效性，以及供体来源外周血干细胞输注治疗持续性全血细胞减少）发布日期: 2023-07-21 原文...
CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the trea
CAR stands for chimeric antigen receptor, which represents the genetically engineered portion of the T cell. The CAR part of the T cell contains proteins that allow the T cells to recognize the specific cancer cells as well as become highly activated to kill the cancer cells. Once in the ...
CAR T Cells ready for infusion. Credit: Penn Medicine 这一研究由CAR-T领域的“大牛”——宾夕法尼亚大学Carl H. June教授带领团队完成,相关成果发表在《Nature Medicine》期刊。 Carl H. June团队采用的CAR-T策略是改变患者自身的免疫T细胞——采集至体外利用嵌合抗原受体(CARs)进行修饰,使其能够特异性识别...